ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) Short Interest Down 20.6% in April

ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) was the recipient of a large decrease in short interest in April. As of April 15th, there was short interest totalling 460,800 shares, a decrease of 20.6% from the March 31st total of 580,600 shares. Approximately 6.1% of the shares of the company are short sold. Based on an average trading volume of 2,410,000 shares, the short-interest ratio is currently 0.2 days.

ZyVersa Therapeutics Stock Performance

NASDAQ ZVSA opened at $4.99 on Friday. ZyVersa Therapeutics has a one year low of $4.44 and a one year high of $220.85. The stock’s 50 day simple moving average is $7.64 and its 200 day simple moving average is $14.72.

Analyst Ratings Changes

Separately, HC Wainwright reissued a “buy” rating and issued a $120.00 target price on shares of ZyVersa Therapeutics in a report on Tuesday, March 26th.

ZyVersa Therapeutics Company Profile

ZyVersa Therapeutics, Inc, a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. The company engages in the development of VAR 200, a cholesterol efflux mediator, which is in Phase 2a clinical trial to the treatment of multiple renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic nephropathy; and IC 100, a monoclonal antibody inflammasome ASC inhibitor that is in preclinical stage for treatment of multitude of inflammatory diseases.